Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.44 |
| ▸ | HTR2C | P28335 | 14/20 | 0.44 |
| ▸ | HTR2B | P41595 | 13/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177869 | 1.00 | HTR2A (0.44) | HTR2AHTR2CHTR2BGSK3BLATS1 | |
| Hydrochloric Acid SCHEMBL5733483 | 0.98 | HTR2A (0.43) | HTR2AHTR2CHTR2BGSK3BLATS1 | |
| Tert-Butyl Formate SCHEMBL27606399 | 0.85 | GSK3B (0.38) | HTR2AHTR2CHTR2BGSK3B | |
| SCHEMBL6200965 | 0.81 | HTR2C (0.41) | HTR2AHTR2CHTR2B | |
| SCHEMBL13931360 | 0.81 | HTR2C (0.53) | HTR2AHTR2CHTR2B | |
| SCHEMBL4308092 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL4308089 | 0.77 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL4308087 | 0.77 | HTR2C (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL2639565 | 0.77 | HTR2C (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL6219727 | 0.75 | HTR2A (0.53) | HTR2AHTR2CHTR2BGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | claimed |
| CN-100334082-C | Process for preparing 2-methylpiperazine derivatives | BIOVITRUM AB (SE) | 2007-08-29 | — | — | CN | claimed |
| CN-100999501-A | Process for the preparation of 2-methyl piperazine derivatives | BIOVITRUM AB (SE) | 2007-07-18 | — | — | CN | claimed |
| US-7129354-B2 | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds | BIOVITRUM AB (SE) | 2006-10-31 | — | — | US | claimed |
| EP-1529043-B1 | Process for the preparation of 2-methyl piperazine derivatives. | BIOVITRUM AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-20060142578-A1 | Novel process | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-06-29 | — | — | US | claimed |
| CN-1662523-A | Novel process | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | claimed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | claimed |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| CN-1360583-A | Novel compounds, their use and preparation | BIOWHEAT RHOM AB (SE) | 2002-07-24 | — | — | CN | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | HTR2A 3/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | HTR2A 16/4885HTR2C 6/4885HTR2B 14/4885 |
| US-20060142578-A1 | Novel process | HTR1A, TPH1, HTR5A | HTR2A 14/4885HTR2C 6/4885HTR2B 8/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR2A 3/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR2A 3/4885HTR2C 1/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.